Still GLP-1 friendly
8 This study, which took place over a five-year period, surely contributed to the FDAs approval of semaglutide in early 2024 for use in this population, and demonstrated that, in addition to managing diabetes and obesity, GLP1 receptor agonists offer value in reducing cardiovascular event risk
Song WJ, Seshadri M, Ashraf U, Mdluli T, Mondal P, et al
Lance Card Thoroughly impressed by their professionalism and dedication Ive had the pleasure of working with this law firm, and I am thoroughly impressed by their professionalism and dedication
In one study, it was demonstrated that exendin-4 prevented LPS-induced depressive-like symptoms in rats and displayed antidepressant-like properties measured in the forced swim test, but this effect was not mediated by the modulation of neuroinflammatory processes, since the levels of IL-1 and TNF- were not affected by exendin-4 treatment [67]